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The endocannabinoid system consists of endogenous lipid mediators and cannabinoid receptors (CB) 1 and 2. It has previously
been demonstrated that activation of the leukocyte-expressed CB2 has anti-inﬂammatory eﬀects in vivo. Here, we report its role
under baseline conditions and in a model of low-dose endotoxemia by comparing CB2 knockout to littermate control mice.
CB2-deﬁcient mice displayed signiﬁcantly more neutrophils and fewer monocytes in the bone marrow under steady state. In
initial validation experiments, administration of 1mg/kg LPS to male C57BL/6J mice was shown to transiently upregulate
systemic proinﬂammatory mediators (peaked at 2 hours) and mobilise bone marrow neutrophils and monocytes into
circulation. In CB2 knockout mice, the level of the metalloproteinase MMP-9 was signiﬁcantly elevated by 2 hours and we also
observed augmented recruitment of neutrophils to the spleen in addition to increased levels of Ccl2, Ccl3, Cxcl10, and Il6.
Collectively, our data show that the absence of CB2 receptor increases the levels of innate immune cell populations in the bone
marrow under steady state. Furthermore, during an acute systemic inﬂammatory insult, we observe a highly reproducible and
site-speciﬁc increase in neutrophil recruitment and proinﬂammatory chemokine expression in the spleen of CB2 knockout mice.
1. Introduction
The endocannabinoid system is an endogenous pathway
which comprises two G protein-coupled (GPCRs) canna-
binoid receptors (CB1 and CB2) [1, 2], the endogenous mem-
brane phospholipid-derived ligands called endocannabinoids
[3], the enzymes that synthesise and degrade them [4–7], and
their transporters across cell membranes [8].
Cannabinoid receptor 1 (CB1) is expressed in the central
nervous system predominantly by neurons [9, 10] andmodu-
lates physiological processes, such as motor behaviour, learn-
ing, memory and cognition, and pain perception [11]. In
contrast, cannabinoid receptor 2 (CB2) is mainly expressed
by immune cells in the periphery [12–14] and has been
reported to possess anti-inﬂammatory properties in several
preclinical disease models [15]. Due to the lack of psycho-
tropic side-eﬀects, CB2 agonists are considered to be a
promising therapeutic strategy for the treatment of chronic
inﬂammatory diseases, such as rheumatoid arthritis, ath-
erosclerosis, and inﬂammatory bowel disease [15].
Sepsis is a systemic inﬂammatory syndrome initiated by
Gram-negative and Gram-positive bacteria and fungi
which infect the lungs, abdomen, bloodstream, and renal or
genitourinary tracts [16]. Sepsis patients ultimately die of
multiorgan failure which is caused by extensive tissue hypox-
ygenation due to ongoingmicrovascular leakage, disseminated
intravascular coagulation, compromised energy production,
and metabolic alterations [17–19]. Sepsis is characterised
by an early systemic inﬂammatory response phase featured
by symptoms, such as tachycardia, fever, hyperventilation,
and activation of the complement and coagulation cascades
[20, 21]. However, it is now appreciated that a compensatory
anti-inﬂammatory response phase follows, characterised by
neuroendocrine-mediated immunosuppression [22, 23].
CB2 activation has been explored as a potential therapeu-
tic intervention in preclinical models of sepsis. CB2 agonism
has been shown to ameliorate the secretion of proinﬂamma-
tory cytokines and chemokines by peritoneal and splenic leu-
kocytes and reduce the recruitment of neutrophils to the
lungs [24, 25]. Similarly, fewer leukocytes adhere to small
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vessels in rodents treated with CB2-selective agonists or
endocannabinoid-degrading enzyme inhibitors [26–29].
However, the literature contains conﬂicting reports as Csoka
et al. recently reported a proinﬂammatory role for CB2 in the
caecal ligation and puncture (CLP) model of sepsis [30].
MMP-9 is a member of the enzyme family of metallopro-
teinases and catalyses the degradation of extracellular matrix
proteins. It has been previously described to mediate tissue
remodelling under physiological and pathophysiological
conditions, and its expression is upregulated to stimulate
immune responses in diseases, such as arthritis, diabetes,
and cancer [31]. A MMP-9-induced immune function that
has been extensively studied in the past is neutrophil
transmigration across basement membrane [32]. In vivo,
MMP-9 release by nonhematopoietic cells drives neutrophil
recruitment to inﬂuenza virus-infected airways [33] and
promotes neutrophil and T cell mobilisation to the postis-
chemic liver in mice [34]. Similarly, MMP-9 deletion protects
mice from endotoxic shock and sepsis; therefore, MMP-9
inhibition has been proposed as a potential therapeutic
approach to treat human sepsis [35].
In the present study, we demonstrate that the myeloid
compartment of the bone marrow which provides the
periphery with leukocytes during systemic inﬂammation is
dysregulated in CB2 knockout mice under steady state. We
went on to study the eﬀects of CB2 deﬁciency on the kinetic
parameters of proinﬂammatory mediator production and
leukocyte mobilization in a low-dose endotoxemia model.
We found that the absence of CB2 results in increased levels
of MMP-9 in the serum at 2 hours and enhanced neutrophil
recruitment to the spleen. Collectively, our data suggest that
this GPCR modiﬁes immune cell migration to peripheral tis-
sues in the context of acute systemic inﬂammatory response.
2. Materials and Methods
2.1. Materials. FBS, LPS from E. coli (O127:B8), HEPES, BSA,
heparin, and paraformaldehyde (PFA) were purchased from
Sigma-Aldrich (Gillingham, UK). PBS was from Lonza
(Slough, UK). EDTA was purchased from VWR technologies
(East Grinstead, UK). HBSS was purchased from Life
Technologies (MA, USA).
2.2. Animals. All animal studies were conducted with ethical
approval from the Dunn School of Pathology Animal
Welfare Ethical Review Board and in accordance with the
UK Home Oﬃce regulations (Guidance on the Operation
of Animals, Scientiﬁc Procedures Act, 1986). Male 8- to 10-
week-old C57BL/6 mice were purchased from the Biomedical
Services Unit (Oxford, UK) and were housed in a 12-hour
light/12-hour dark cycle unit with free access to food and
water. CB2 knockout animals backcrossed ﬁve times to
C57BL/6 genetic background were purchased from the
Jackson Laboratory (ME, USA) and were further backcrossed
for an additional ﬁve generations to C57BL/6 mice before
use. Power calculations were carried out prior to all in vivo
experiments to determine the minimum number of animals
needed to detect an eﬀect of at least 30% with p < 0 05
between wild-type and CB2 knockout mice.
2.3. Endotoxemia Model. Male C57BL/6J and CB2 knockout
mice were injected intraperitoneally (i.p.) with 1mg/kg LPS
and were monitored until sacriﬁce at 1, 2, 4, and 8 hours.
Naïve animals were used for the steady state measurements.
All animals were euthanised via asphyxiation with a rising
concentration of CO2. The peritoneal cavities were lavaged
with 5ml ice-cold PE (PBS/2mM EDTA) buﬀer and blood
was retrieved from the hepatic vein into heparin- (10U/ml-)
treated tubes. Blood was left to clot for 5 hours at 4°C and
serum was collected after a 10min centrifugation at 8000×g.
The lungs, spleen, and bone marrow were harvested and
stored on ice until further processing.
2.4. Tissue Processing. Lungs were homogenised and were
incubated for 1 hour in 1mg/ml Collagenase D (Roche,
Welwyn Garden City, UK) at 37°C/5% CO2. The homoge-
nates were then passed through 70μm cell strainers and were
prepared for ﬂow cytometry.
Spleens were cut into 75mm3 pieces and digested
enzymatically in collagenase D, while bone marrow cells were
ﬂushed from murine femora in 10ml PBS. The lysates were
resuspended in 1ml PBS, and 200μl were mixed with 2ml
BD Pharm Lyse buﬀer (BD Biosciences, Oxford, UK) for
15min at room temperature to lyse red blood cells. Cells were
then washed twice with 1% BSA in PBS and were stained
according to the ﬂow cytometry protocol.
Fresh blood (50μl) were stained according to the ﬂow
cytometry protocol and red blood cells were lysed with the
BD FACS lysis solution (BD Biosciences) for 5min at
room temperature. Samples were then washed twice with
FACS buﬀer.
2.5. Flow Cytometry. Harvested cells were blocked with 5%
FBS in PBS for 15min on ice and were then stained with
anti-CD45 (30-F11; BD Pharmigen), anti-Ly-6G (1A8; BD
Pharmigen), anti-Ly-6G (1A8; Biolegend), anti-Ly-6B.2 (7/4;
Abd Serotec), anti-CD11b (M1/70; Biolegend), anti-Ly-6C
(HK1.4; Biolegend), and anti-CD115 (AFS98; Biolegend) at
2μg/ml in FACS buﬀer (PBS; 2%FBS, 25mM HEPES, 5mM
EDTA) for 30min on ice protected from light. Cells were
pelleted at 5000× g for 10min and resuspended in 1% PFA.
Samples were run on a Dako Cyan ADP ﬂow cytometer
(Beckman Coulter Ltd., High Wycombe, UK) and analysed
with FlowJo v10.0.8 software (Tree Star Inc., Ashland, USA).
2.6. Cytokine, Chemokine, and Growth Factor Level
Measurement. In the time course experiment, cytokine and
chemokine serum levels were measured by ELISA as
instructed by the manufacturer (R&D systems, Abingdon,
UK). Comparison of WT and CB2 knockout animal serum
cytokine and chemokine levels were assessed by a Magnetic
Luminex Screening Assay as instructed by the manufacturer
(R&D systems) at a Bio-Plex 200 system (Bio-Rad, Hemel
Hempstead, UK). Granulocyte colony-stimulating factor
(G-CSF) levels in the serum of WT, and CB2 knockout
animal was quantiﬁed with a Quantikine ELISA (R&D
systems) following the instructions of the manufacturer. All
samples were diluted in reagent diluent to be in the linear
part of the standard curve.
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2.7. qPCR. RNA extraction was carried out with the
RNeasy kit (Qiagen, Manchester, UK), and RNA quality
was veriﬁed with a ND-100 spectrophotometer (Nano
Drop Technologies, DE, USA). cDNA was synthesized
from 400 to 600ng RNA using the QuantiTect Reverse
Transcription kit (Qiagen) according to the manufacturer’s
instructions. cDNA (20–30 ng) was used as a template in
qPCR experiments using speciﬁc primers (500 nM) and
2X Sybr Select (Life Technologies) as the detection
chemistry. The qRT-PCR thermal proﬁle consisted of one
step at 95°C for 5min, one step of 40 cycles of 95°C for
20 s, 60°C for 20 s, and 72°C for 20 s, and the ﬁnal
elongation step at 72°C for 5min. Melt curve analysis
was run after every experiment. The experiments were
carried out with a Step One Plus platform (Applied
Biosystems, MA, USA) and analysed with the StepOne
software. Il6, Ccl3, Cxcl10, and Cmtm6 primer pairs were
purchased from Qiagen. Actg1 was the chosen reference
gene (Table 1). Cycle threshold (Ct) values were determined,
and relative mRNA contents were inferred from normaliza-
tion of the gene of interest expression to that of the
housekeeping gene (ΔCt). Relative expression results were
plotted as 2^(−ΔCt).
2.8. Cell Counts. To calculate the number of leukocytes in
blood and tissues, 300μl of samples were mixed 12.5μl with
CountBright Absolute Counting Beads (Life Technologies)
and were run on a Dako Cyan ADP ﬂow cytometer.
Numbers were determined from the cell : bead ratio on
the forward/side scatter ﬂow cytometry plot as instructed
by the manufacturer.
2.9. PCR Arrays. The Mouse Chemokines & Receptors PCR
array (Qiagen) was used as instructed by the manufacturer.
Brieﬂy, pooled RNA samples (400 ng each) from 9 wild-
type and CB2 knockout murine spleens were reversed
transcribed using the QuantiTect Reverse Transcription kit
(Qiagen), and the RT2 qPCR mastermix (including cDNA)
was aliquoted across the provided PCR arrays. A fast
protocol was followed consisting of one step at 95°C for
10min and one step of 40 cycles of 95°C for 15 s and 60°C
for 1min. Melt curve analysis was run after every experiment.
Experiments were carried out with the Step One Plus
platform (Applied Biosystems) and analysed with the
StepOne software. Relative expression against endogenous
Gapdh was plotted as 2^(−ΔCt).
2.10. Statistical Analysis.All data are reported as mean+ SEM
of several independent experiments. Statistical analysis was
carried out with GraphPad Prism 6.0 (CA, USA). A Grubbs’
test was performed before statistical analysis to remove
signiﬁcant outliers from the datasets (GraphPad Prism). A
student t-test was used to analyse experiments with two sets
of normally distributed data, whereas two-way ANOVA with
Sidak’s post hoc multiple comparisons test was used to
assess the inﬂuence of two independent categorical variables
in experiments with one continuous dependent variable.
Results were considered signiﬁcant when p < 0 05.
3. Results
3.1. Neutrophils and Monocytes Are Recruited to the Lungs
and Peritoneal Cavity upon LPS Administration. We ﬁrst
carried out a time course evaluation of innate immune cell
recruitment to peripheral tissues in order to understand
the cellular kinetics in the endotoxemia model. We
therefore administered i.p. 1mg/kg LPS into male C57BL/6J
mice sacriﬁced at 1, 2, 4, and 8 hours. As shown in
Figure 1(a), neutrophils (CD45+Ly-6GhiLy-6B.2+) inﬁltrated
the peritoneum at 2 hours and were found at all subsequent
time points studied. Similarly, neutrophil and monocyte
(CD45+Ly-6GmidLy-6B.2+) populations inﬁltrated the lungs
at the 2-hour time point (Figure 1(b)). Neutrophils were
also detected in the livers of endotoxemic mice from 2
hours (data not shown).
We next sought to assess the inﬂammation score in these
organs. We chose IL-6 because it has been shown to be a good
predictor of disease progression and mortality in humans
[36, 37], CCL2 as the main chemokine responsible for
inﬂammatory monocyte recruitment to inﬂamed tissues
[38, 39] and CXCL1, CXCL2, and CXCL5 as the murine
analogues of human IL-8 which control neutrophil migration
to injury sites [40]. Proinﬂammatory mediators in the
peritoneal ﬂuid of endotoxemic mice followed diﬀerent
kinetic patterns, and their levels peaked between 2 and 4
hours upon LPS administration. Subsequently, they decreased
with IL-6 and CXCL1 levels falling below the detection limit
(Figures 1(c), 1(d), and 1(e)). In the lungs, the mRNA levels
of Il6 and Ccl2 peaked at 2 hours and decreased by 8 hours,
whereas Cxcl1 expression peaked at 4 hours (Figures 1(f),
1(g), and 1(h)).
Collectively, these observations show that low-dose LPS
administration induces the recruitment of neutrophils and
monocytes to peripheral tissues where a range of proinﬂam-
matory mediators are released. The pattern of leukocyte
recruitment displays a continuous increase trend, whereas
inﬂammatory mediator production peaks at 2 hours and is
decreased until 8 hours post LPS administration.
3.2. Characterisation of ProinﬂammatoryMediator Production
during Endotoxemia Time Course. We next looked into the
systemic levels of proinﬂammatory mediators at 1, 2, 4,
and 8 hours post LPS. Measurement of proinﬂammatory
cytokines and chemokines showed that all mediators apart
from TNF-α reach a peak at 2 hours post LPS administra-
tion and are subsequently reduced as shown at the 8-hour
Table 1: Primers used for detection of proinﬂammatory mediator
expression in murine lungs.
Gene Primer Primer sequence (5′→ 3′)
Mm_Ccl2
Sense CAGCACCTTTGAATGTGAAGTTG
Antisense TGCTTGAGGTGGTTGTGGAA
Mm_Cxcl1
Sense AAGTCATAGCCACACTCAAG
Antisense CAGACAGGTGCCATCAGA
Mm_Actg1
Sense CCAACAGCAGACTTCCAGGATT
Antisense CTGGCAAGAAGGAGTGGTAACTG
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time point (Figure 2). TNF-α levels peaked at 1 hour and they
were detectable until the 2-hour time point (Figure 2(a)), while
IL-6, CCL2, CXCL1, and CXCL2 were still present at later time
points (Figures 2(b), 2(c), 2(d), and 2(e)). Finally, one of the
three analogues of human IL-8 in mice, CXCL5, displayed a
transient secretion pattern in the endotoxemic serum between
2 and 4 hours (Figure 2(f)), while the anti-inﬂammatory
cytokine IL-10 was undetectable at all selected time points
(data not shown). Taken together, our data suggest that
proinﬂammatory mediators in the circulation are rapidly
upregulated within the ﬁrst 2 hours upon LPS administration.
3.3. CB2 Deﬁciency Does Not Regulate Cytokine or Chemokine
Secretion but Signiﬁcantly Augments MMP-9 Levels. To test
whether a functional CB2 receptor has the ability to modulate
proinﬂammatory mediator secretion in the endotoxemic
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Figure 1: Immune cell recruitment to peripheral tissues is maximal at 2 hours post LPS challenge. Male C57BL/6J mice (8–10 weeks old) were
administered i.p. with 1mg/kg LPS and innate immune cell recruitment to peripheral tissues, and production of proinﬂammatory mediators
was followed for 8 hours. Naïve animals were used for the steady state measurements. Peritoneal lavage ﬂuid (a) and lungs (b) were harvested
to assess the presence of neutrophils (CD45+Ly-6GhiLy-6B.2+) and monocytes (CD45+Ly-6GmidLy-6B.2+) by ﬂow cytometry. Representative
dot plot graphs gated on CD45+ cells are shown for the peritoneum (a) and lungs (b). The levels of the cytokine IL-6 (c) and
chemokines CCL2 (d) and CXCL1 (e) were measured in peritoneal ﬂuid by ELISA. The mRNA levels of Il6 (f), Ccl2 (g), and Cxcl1
(h) in lung homogenates were measured by qRT-PCR. Data are from one experiment with 5-6 mice per time point. Mean + SEM are
represented in all bar graphs. ND: not detected.
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serum, we injected 1mg/kg LPS into male C57BL/6J and CB2
knockout mice for 2 hours. We hypothesised that if CB2
ameliorated disease severity, CB2-deﬁcient mice would have
elevated proinﬂammatory mediator levels in their serum at
the 2-hour time point.
The concentrations of cytokine and chemokine media-
tors evaluated in the serum of C57BL/6J and CB2 knockout
mice were comparable (Figures 3(a), 3(b), 3(c), 3(d), 3(e),
3(f), 3(g), and 3(h)). Interestingly, secreted metalloproteinase
MMP-9, which has a role in neutrophil migration [32], was
signiﬁcantly upregulated in the serum of CB2 knockout
animals (p < 0 01). This ﬁnding suggested that CB2 may be
regulating neutrophil recruitment in this acute model of
inﬂammation. We therefore decided to examine neutrophil
inﬁltration to peripheral tissues.
3.4. CB2 Genetic Ablation Does Not Aﬀect Neutrophil
Recruitment to the Lungs. The lungs are routinely selected
as the major site of leukocyte recruitment in sepsis
models. Assessment of neutrophil and monocyte recruit-
ment to the lungs at 2 hours revealed comparable numbers
of neutrophils (CD45+Ly-6GhiLy-6B.2+) and monocytes
(CD45+Ly-6GmidLy-6B.2+) in both wild-type and CB2
knockout mice (Figures 4(c) and 4(d)). Similar observations
were made at the later time point of 8 hours (Figures 4(c)
and 4(d)). We analysed the inﬂammation score in this tissue
by measuring the mRNA levels of proinﬂammatory
mediators in lung homogenates at both time points. We
found that Il6 (Figure 4(e)) and Ccl2 (Figure 4(f)) levels are
signiﬁcantly downregulated in the CB2 knockout lungs
(p < 0 05), while Cxcl1 displayed a nonsigniﬁcant reduction
trend (Figure 4(g)). These data suggest that CB2 does not
regulate neutrophil inﬁltration to the lungs during acute
systemic inﬂammation.
3.5. CB2 Knockout Animals Have a Bigger Neutrophil
Population in the Bone Marrow under Steady State. The bone
marrow plays an integral part in sepsis by replenishing
leukocyte numbers in the circulation via G-CSF-triggered
emergency myelopoiesis [41]. To investigate the role of this
tissue in neutrophil and monocyte mobilisation in the
absence of CB2, we harvested bone marrow from male
C57BL/6J and CB2 knockout mice femora following
endotoxemia for 2 and 8 hours and counted the numbers of
the immune cell populations by ﬂow cytometry. Naïve mice
served as the steady state control.
Bone marrow assessment under steady state revealed dif-
ferences in neutrophil (CD45+CD11b+Ly-6GhiLy-6C+) and
monocyte (CD45+CD11b+Ly-6GmidLy-6C+) populations
(Figures 5(a) and 5(b)). CB2-deﬁcient mice had signiﬁcantly
more neutrophils (p < 0 05) and signiﬁcantly fewer
monocytes (p < 0 05) in the bone marrow in comparison
with their control littermates (Figures 5(c) and 5(d)). During
endotoxemia, the numbers of neutrophil and monocyte in
bone marrow were sharply reduced (p < 0 0001) in both
C57BL/6J and CB2 knockout mice (Figures 5(c) and 5(d)).
In particular, neutrophil numbers declined to 35% and 8%
in wild-type mice at 2 and 8 hours, respectively, upon
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Figure 2: Proinﬂammatory mediator levels peak at 2 hours post LPS challenge. Male C57BL/6J mice (8–10 weeks old) were administered i.p.
with 1mg/kg LPS and the levels of proinﬂammatory mediators in the serum was measured up to 8 hours post challenge. The levels of
TNF-α (a), IL-6 (b), CCL2 (c), CXCL1 (d), CXCL2 (e), and CXCL5 (f) were measured in the serum by ELISA. Data are from one
experiment with 5-6 mice per time point. Mean + SEM are represented in all bar graphs. ND: not detected.
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LPS administration, whereas their numbers fell to 28% and
13% in CB2 knockout mice (Figure 5(c)). Monocytes
decreased by 28% at 8 hours in wild-type mice, in stark
contrast to CB2 knockout mice where a reduction of 57%
was observed (Figure 5(d)).
3.6. Increased Neutrophil Mobilisation in CB2 Knockout
Mice Spleens. Apart from the bone marrow, neutrophils
have also been reported to reside in other tissues, such as
the spleen and the liver where marginated populations are
in a two-way equilibrium with the bloodstream [42, 43].
The substantial egress of neutrophils from the bone marrow
at the peak 2h time point suggested that there might be other
peripheral organs where neutrophil recruitment might be
dysregulated in CB2 knockout mice during endotoxemia.
For this reason, we injected 1mg/kg LPS to male C57BL/6J
and CB2 knockout mice for 2 and 8 hours and counted neu-
trophil numbers in the blood, peritoneal cavity, and spleen by
ﬂow cytometry.
Neutrophil (CD45+CD11b+Ly-6GhiLy-6C+) numbers in
the blood were comparable between the two genotypes under
steady state and they were signiﬁcantly (p < 0 0001) elevated
during endotoxemia. Nevertheless, we did not observe a
statistically signiﬁcant diﬀerence between C57BL/6J and
CB2 knockout mice at any time point studied. Congruent
with this, serum G-CSF levels were comparable between
the two genotypes (data not shown). We next measured
neutrophil (CD45+Ly-6GhiLy-6B.2+) levels in the peritoneal
cavity as the site of sterile infection; however, numbers were
also similar between wild-type and CB2 knockout mice (data
not shown).
We ﬁnally looked at the population of splenic neutrophils
between wild-type and CB2 knockout mice during endotoxe-
mia (Figures 6(a), 6(b), and 6(c)). Acute splenitis has been
documented in necropsies from human septic patients [44],
and this tissue has been reported to play a crucial role in
clearance of pathogens and activation of adaptive immunity
in sepsis [45, 46]. At 2 hours, we observed a signiﬁcant
(p < 0 05) increase in neutrophil levels in the spleens of CB2
knockout mice. Interestingly, at 8 hours, the splenic
neutrophil numbers were comparable between wild-type
and CB2 knockout animals (Figure 6(c)). Collectively, our data
show that the absence of CB2 leads to rapid and enhanced
neutrophil inﬁltration to the spleen during endotoxemia.
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Figure 3: CB2 deﬁciency results in higher MMP-9 levels in the serum of endotoxemic mice. Male C57BL/6J and CB2 knockout mice (8–10
weeks old) were administered i.p. with 1mg/kg LPS and the levels of proinﬂammatory mediators in the serum at 2 hours was measured. The
levels of TNF-α (a), IL-6 (b), CCL2 (c), CCL3 (d), CCL4 (e), CXCL1 (f), CXCL5 (g), CXCL10 (h), and MMP-9 (i) were measured in serum
samples by Luminex. Data are from two independent experiments with 6–9 mice per group and 3–5 mice per group per experiment. Mean
+ SEM are represented in all bar graphs and data were analysed with a one-tailed student t-test, ∗∗p < 0 01.
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To understand the mechanism, we screened for diﬀeren-
tially expressed genes between pooled RNA samples from
spleens of wild-type and CB2 knockout mice administered
with 1mg/kg LPS for 2 hours using a murine chemokine
and chemokine receptors gene array. As shown in Table 2,
there were 72 out of 84 genes in the array for which expres-
sion was detectable (ΔCt≤ 12 when normalised to endoge-
nous Gapdh) in either wild-type or CB2 knockout pooled
tissue samples. To identify genes where expression was most
altered in the CB2 knockout spleens, we applied a cutoﬀ fold
change of 2 to the preliminary list (Table 2).
This ﬁlter removed 67 genes, and the 5 genes that satis-
ﬁed the exclusion criteria were further explored: the chemo-
kines Ccl2, Ccl3, and Cxcl10 and the neutrophil chemotaxis
and degranulation marker Cmtm6 and the cytokine Il6. We
proceeded to validate the expression of the genes with qPCR.
Our ﬁndings conﬁrmed the Ccl2, Cxcl10, and Il6 data from
the PCR array as we observed a signiﬁcant (p < 0 05) upreg-
ulation (p < 0 01 for Ccl3 mRNA levels) of their expression
in CB2 knockout spleens (Figures 6(d), 6(e), 6(f), and 6(g)).
In contrast, Cmtm levels were undetectable (data not shown).
In conclusion, CB2 knockout spleens express higher mRNA
Ly
-6
G
Ly-6B.2
Gated on CD45+ cells Gated on CD45+ cells
Ly
-6
G
Ly-6B.2
2 hours 8 hours
W
T
25.9
14.1
34.0
16.0
(a)
Ly
-6
G
Ly-6B.2
Ly
-6
G
Ly-6B.2
KO
25.4
13.9
28.7
14.1
Gated on CD45+ cells Gated on CD45+ cells
2 hours 8 hours
(b)
N
eu
tro
ph
ils
 (×
10
3 )
2 8
0
50
100
150
Time (hours)
KO
WT
(c)
0
20
40
60
2 8
KO
WT
Time (hours)
M
on
oc
yt
es
 (×
10
3 )
(d)
m
RN
A
 ex
pr
es
sio
n 
ov
er
 ac
tin Il6
0
0.005
0.010
0.015
0.020
0.025
WT KO
⁎
(e)
Ccl2
m
RN
A
 ex
pr
es
sio
n 
ov
er
 ac
tin
0
0.02
0.04
0.06
0.08
0.10
WT KO
⁎
(f)
Cxcl1
m
RN
A
 ex
pr
es
sio
n 
ov
er
 ac
tin
0
0.01
0.02
0.03
0.04
0.05
WT KO
(g)
Figure 4: CB2 knockout mice have comparable numbers of neutrophils and monocytes in the lungs following LPS challenge. Male C57BL/6J
and CB2 knockout mice (8–10 weeks old) were administered i.p. with 1mg/kg LPS and innate immune cell recruitment to the lungs was
studied at 2 and 8 hours. Lung homogenates were stained for neutrophils (CD45+Ly-6GhiLy-6B.2+) and monocytes (CD45+Ly-6GmidLy-6B.2+)
by ﬂow cytometry. Representative dot plot graphs gated on CD45+ cells are shown from one C57BL/6J (a) and one CB2 knockout (b) mouse
for each time point. Pooled data from two independent experiments with 8-9 mice per group are shown for neutrophils (c) and for monocytes
(d). (e–g) Proinﬂammatory mediator mRNA expression was measured in lung homogenates from wild-type and CB2 knockout murine lungs
at 2 hours by qRT-PCR. Data for Il6 (e), Ccl2 (f), and Cxcl1 (g) are pooled from two independent experiments with 8-9 mice per
group and 4-5 mice per group per experiment. Mean+ SEM are represented in all bar graphs and data were analysed with a one-tailed
student t-test (e–g) or a two-way ANOVA with Sidak’s post hoc multiple comparisons test (b, d), ∗p < 0 05.
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levels of CC, CXC chemokines, and Il6 which suggests a
chemokine-dependent mobilisation of neutrophils to this
tissue in CB2 knockout mice.
4. Discussion
In the present study, we report for the ﬁrst time that CB2
deﬁciency in mice leads to more neutrophils and fewer
monocytes in the bone marrow under steady state. Moreover,
we observed a CB2-dependent suppression of neutrophil
recruitment to the spleen at the 2-hour time point of the
low-dose endotoxemia model which coincides with elevated
levels of MMP-9 in the serum of the animals.
Endotoxemia is frequently employed to model sepsis in
animals [47]. The model used in this study recapitulates the
main features of endotoxemia, namely, the overwhelming
innate immune response and the rapid but transient systemic
upregulation of proinﬂammatory cytokines and chemokines.
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Figure 5: CB2 knockout mice display elevated neutrophils and monocytes in the bone marrow compared to littermate controls. Male C57BL/
6J and CB2 knockout mice (8–10 weeks old) were administered i.p. with 1mg/kg LPS and innate immune cell population numbers in the bone
marrow were assessed for up to 8 hours. Flushed bone marrow cells from the animal femora were stained for neutrophils (CD45+CD11b+Ly-
6GhiLy-6C+) and monocytes (CD45+CD11b+Ly-6GmidLy-6C+) by ﬂow cytometry. Representative dot plot graphs from one C57BL/6J (a) and
CB2 knockout (b) mouse gated on CD45
+CD11b+ cells are shown for the full time course. Pooled data from two independent experiments
with 7–10 mice per group and 3–5 mice per group per experiment are shown for neutrophils (c) and monocytes (d). Mean + SEM are
represented in all bar graphs and data were analysed with a two-way ANOVA with Sidak’s post hoc multiple comparisons test, ∗p < 0 05.
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Figure 6: CB2 knockout mice have increased neutrophils in the spleen at 2 hours following LPS challenge. Male C57BL/6J and CB2 knockout
mice (8–10 weeks old) were administered i.p. with 1mg/kg LPS for 8 hours and neutrophil numbers in the spleen were assessed for 8 hours.
Spleen homogenates were stained for neutrophils (CD45+CD11b+Ly-6GhiLy-6C+) by ﬂow cytometry. Representative dot plot graphs from
one C57BL/6J (a) and one CB2 knockout (b) mouse gated on CD45
+CD11b+ cells are shown for the full time course. Pooled data from
two independent experiments with 7–10 mice per group are shown for neutrophils in (c). Mean + SEM are represented in the bar graph,
and data were analysed with two-way ANOVA with Sidak’s post hoc multiple comparisons test, ∗∗p < 0 01. The mRNA levels of (d) Ccl2,
(e) Ccl3, (f) Cxcl10, and (g) Il6 were tested by qPCR. Data are pooled from two independent experiments with 8-9 mice per group and 4-5
mice per group per experiment. Mean + SEM are represented in all bar graphs and data were analysed with a one-tailed student t-test,
∗p < 0 05, ∗∗p < 0 01.
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However, although it has been shown that LPS is pathologi-
cally important in human sepsis, endotoxemia models are
subject to limitations, and thus their suitability for preclinical
trials should be determined by the tested hypothesis. Thus,
the ﬁndings from these models should be related to the
clinical manifestations of sepsis with caution [48, 49]. We
therefore decided to use a low-dose endotoxemia model to
study the eﬀects of CB2 in the context of acute systemic
inﬂammation. Although a low LPS dosage may not exhibit
the severe physiological insult present in high-dose endo-
toxin and bacterial infection models, its advantage is that it
can be used to measure the eﬀects of anti-inﬂammatory drugs
or gene deletion without severely aﬀecting the welfare of
experimental animals.
Our data demonstrates that the chosen LPS dose and
route of administration result in proinﬂammatory mediator
secretion and leukocyte recruitment in the lungs and the
peritoneum. Neutrophils were the main immune cell type
inﬁltrating the lungs and the peritoneal cavity consistent
with the CXCL1 expression pattern in the periphery. This
Table 2: Chemokine and receptor mRNA expression in spleens of
wild-type and CB2 knockout mice. Male C57BL/6J mice (8–10
weeks old) were administered with 1mg/kg LPS for 2 hours and
were sacriﬁced to harvest spleens. The tissues were homogenised,
RNA was extracted and reverse transcribed to cDNA. Pooled
cDNA from 9 wild-type or CB2 knockout mice was used in
murine chemokine and receptor PCR arrays. Data are normalised
to endogenous Gapdh levels and presented as 2^(−ΔCt).
WT KO Fold change (KO/WT)
c5ar1 0.026 0.03 0.141
ccl11 0.06 0.061 0.022
ccl12 0.029 0.061 1.083
ccl17 0.059 0.061 0.032
ccl19 3.788 3.914 0.033
ccl2 0.247 1.01 3.087
ccl20 0.028 N/A −1
ccl22 0.028 0.03 0.072
ccl25 0.029 0.03 0.03
ccl26 N/A 0.026 N/A
ccl3 0.059 0.245 3.159
ccl4 0.471 0.967 1.052
ccl5 0.471 0.969 1.058
ccl6 0.03 0.062 1.062
ccl7 0.119 0.246 1.058
ccr1 0.029 0.029 0
ccr10 0.029 N/A −1
ccr2 0.027 0.031 0.151
ccr3 0.026 0.029 0.098
ccr4 0.028 0.03 0.042
ccr5 0.061 0.062 0.01
ccr6 0.243 0.492 1.023
ccr7 0.242 0.245 0.011
ccr8 N/A 0.03 N/A
ccr9 N/A 0.029 N/A
ackr4 N/A 0.028 N/A
ccrl2 0.059 0.122 1.066
cmklr1 N/A 0.03 N/A
cmtm3 0.062 0.064 0.035
cmtm4 0.03 N/A −1
cmtm6 0.23 1.01 3.39
cx3cl1 0.028 0.028 0.029
cx3cr1 0.028 0.027 −0.024
cxcl1 0.12 0.123 0.028
cxcl10 1.893 7.87 3.158
cxcl11 0.027 0.03 0.089
cxcl12 0.06 0.062 0.03
cxcl13 0.119 0.245 1.056
cxcl15 0.029 0.029 −0.006
cxcl16 0.03 0.031 0.033
cxcl2 0.121 0.246 1.028
cxcl3 0.028 0.03 0.087
Table 2: Continued.
WT KO Fold change (KO/WT)
cxcl5 0.987 2.035 1.062
cxcl9 0.029 0.063 1.138
cxcr1 N/A 0.028 N/A
cxcr2 N/A 0.03 N/A
cxcr3 0.028 0.028 0.014
cxcr4 0.059 0.031 −0.482
cxcr5 0.119 0.246 1.059
cxcr6 0.029 0.061 1.116
ackr3 N/A 0.029 N/A
ackr1 0.028 0.031 0.12
fpr1 N/A 0.031 N/A
hif1a 0.06 0.123 1.064
ifng 0.031 0.032 0.026
il16 0.059 0.061 0.025
il1b 0.119 0.244 1.048
il4 N/A 0.029 N/A
il6 0.057 0.244 3.284
itgam 0.028 0.031 0.108
itgb2 0.12 0.247 1.067
mapk1 0.059 0.122 1.069
mapk14 0.061 0.124 1.051
pf4 0.058 0.06 0.034
ppbp 0.12 0.124 0.034
slit2 N/A 0.026 N/A
tgfb1 0.119 0.245 1.061
tlr2 0.03 0.031 0.041
tlr4 0.028 0.029 0.034
tnf 0.03 0.061 1.048
xcl1 0.029 0.03 0.036
xcr1 0.028 N/A −1
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is in accordance with previous studies that underlined the
importance of this chemokine in mediating host defence
to pathogens [40]. Interestingly, monocytes were found
to migrate only to the lungs of endotoxemicmice. This ﬁnding
highlights the signiﬁcance of immune cell composition and
architecture of tissues for leukocyte recruitment as previously
shown for neutrophils (reviewed in [50, 51]).
A key ﬁnding of this study was the lack of changes in
systemic levels of proinﬂammatory mediators in endotoxe-
mic mice in the absence of CB2. This is at odds with the
literature as CB2 has been previously shown to regulate
proinﬂammatory cytokine and chemokine secretion and
adhesion molecule expression [24–26]. In contrast, another
study using the same animal model of sepsis showed that
CB2 deﬁciency was responsible for the dramatic drop in the
levels of the same mediators in plasma and peritoneal ﬂuid
[30]. The authors found that tissue injury and bacterial
burden were also reduced in CB2 knockout mice, suggesting
that CB2 is a receptor that contributes to the pathology of
the disease by prolonging host responses. Explanations for
this discrepancy could be the diﬀerent LPS serotypes and
dosages used, the route of LPS administration, and the
animal species used.
The discrepancies between these papers and our own
study may be the choice of the animal model used. The
CLP model has been used widely as it resembles the human
pathology more reliably than endotoxemia models [52].
However, it is a model of severe inﬂammation with IL-6
plasma levels being a signiﬁcant survival predictor [36].
Furthermore, the role of IL-10 in immunosuppression has
been highlighted before and provides an explanation for the
irreversibility of septic shock and the high mortality rates
observed in mice [53, 54]. In our own low-dose LPS model,
IL-6 levels were transient, while IL-10 fell beneath the
detection limit. Therefore, our results interrogate CB2
functions in diﬀerent pathophysiological conditions from
those seen in the CLP model.
The levels of MMP-9 were signiﬁcantly elevated in the
serum of CB2 knockout mice. MMP-9 plays an important
role in neutrophil transmigration via its role in extracellu-
lar matrix degradation and is secreted upon stimulation by
chemotactic factors [32, 55]. CB2 has been previously
shown to aﬀect MMP-9 eﬀector functions in relation to
other immune cells. For instance, MMP-9-dependent
dendritic cell migration is inhibited upon treatment with
the CB2-selective agonist Gp1a [56], whereas CB2 deﬁciency
leads to increased MMP-9 secretion by macrophages in
low-density lipoprotein receptor knockout mice [57].
We report for the ﬁrst time that CB2 regulates MMP-9
levels in a sepsis model, and further investigation is
required to determine whether this accounts for diﬀerences
in neutrophil mobilisation.
One of the main objectives of this study was to assess
leukocyte recruitment to peripheral tissues during acute
systemic inﬂammation. Neutrophils reside marginated in
tissues, such as the lungs, spleen, and liver where they are
in a direct exchange with the circulation [42, 43]. Our results
are in seeming disagreement with the work of Tschöp et al.
who reported augmented recruitment of neutrophils to the
lungs of CB2 knockout mice [24]. One possible reason for
these diﬀerences could be the fact that we have utilised two
diﬀerent models of sepsis which have varying degrees of
inﬂammatory stimulation.
During sepsis, emergency myelopoiesis is triggered in the
bone marrow in response to signals from G-CSF released
in the blood by the injured endothelium [41, 58, 59].
Hematopoietic stem cells proliferate giving rise to neutro-
phils that egress from the bone marrow and enter the
circulation [41, 60]. Our data rule out a role of CB2 in
regulating G-CSF-dependent neutrophil egress from the
bone marrow; however, another plausible explanation is that
CB2 controls neutrophil traﬃcking via direct eﬀects on these
cells. In the literature, there are conﬂicting reports relating
to the use of CB2 agonists on neutrophil recruitment. For
example, the endocannabinoid 2-arachidonoylglycerol is a
neutrophil chemoattractant in vitro [61]. However, natural
and synthetic CB2-selective agonists ameliorate neutrophil
recruitment in models of inﬂammation either directly
[62–64] or indirectly via the regulation of endothelial
proinﬂammatory gene expression [65].
In our experiments, CB2 was shown to control neutrophil
recruitment and or retention to the spleen. The upregulation
of Ccl3 and Cxcl10 in the spleens of CB2 knockout mice
suggests a chemokine-dependent regulation of neutrophil
migration to this organ. CCL3 engages the CCR1 receptor
and has been reported to induce calcium alterations in
polymorphonuclear leukocytes, while genetic deletion of
CCR1 in mice results in a loss of neutrophil mobilisation to
CCL3 in vivo and impaired killing of A. fumigatus conidia
[66]. CXCL10, on the other hand, reduces survival in sepsis
and contributes to the pathology of sepsis [67]. Both CXCL10
and its cognate receptor CXCR3 are expressed by activated
neutrophils and are responsible for their recruitment to the
lungs in acute respiratory distress syndrome models [68,
69]. Our data do not exclude the possibility that CB2, apart
from these chemokines, may also regulate the expression of
their respective receptors on neutrophils. However, further
studies are needed to determine which pathway and cellular
key players are crucial for this eﬀect.
The spleen is an important organ for pathogen clearance
by phagocytosis during infection. Phagocytes, such as
monocytes/resident macrophages and neutrophils are key
players in this process as highlighted by the defects in
bacterial and fungal killing observed in splenectomised
animals and human patients [45, 70]. Furthermore, splenic
neutrophils have been shown to migrate from the mar-
ginal zone to the T cell rich area in a CXC chemokine-
dependent manner and indirectly induce T cell activation
via antigen transfer to dendritic cells [46]. Therefore, we
speculate from the results presented in this study that
the absence of the CB2 receptor may impact the process
of LPS clearance.
One possible limitation of our study is that our data were
not conﬁrmed with pharmacological inhibition in wild-type
littermate animals. To date, three CB2R-selective antagonists
have been developed and used extensively in vitro and in vivo:
SR144528, AM630, and JTE907 [15]. These compounds
inhibit CB2 ligand-induced signalling and displace CB2
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agonist from CB2 in competitive binding assays [71–73].
However, it has also been reported that these antagonists
display nonspeciﬁc activation of ion channels and CB1R
[72, 74–77] and exhibit inverse cannabimimetic eﬀects when
administered by themselves in vivo [71, 72]. For this reason,
we decided to restrict our study to a biological comparison
between WT and CB2R−/− mice in endotoxemia.
In summary, we found that the lack of this GPCR leads to
enhanced retention of neutrophils and increased release of
monocytes in the bone marrow under steady state. We
highlight a critical role for CB2 in regulating neutrophil
inﬁltration to the spleen during acute systemic inﬂammation
(Figure 7). A potential mechanism for this eﬀect is the
increased secretion of MMP-9 and Ccl3/Cxcl10 expression
in the spleens of CB2 knockout mice. Taken together, we
propose a novel role for CB2 in suppressing neutrophil
migration to lymphoid organs under inﬂammatory condi-
tions which we believe warrants further investigation.
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